Ftse Mib
35.090,23
-0,64%
DAX
20.214,79
-0,51%
S&P 500
5.827,04
-1,54%
NASDAQ
19.161,63
-1,63%
Bitcoin
93.875,07
-0,73%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CNS Pharmaceuticals Inc (CNSP) CNS Pharmaceuticals Inc (CNSP) Notizie

CNSP

CNS Pharmaceuticals (CNSP)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CNSP
DataOraFonteTitoloSimboloCompagnia
11/12/202418:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNSPCNS Pharmaceuticals Inc
15/11/202422:19Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:CNSPCNS Pharmaceuticals Inc
14/11/202423:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNSPCNS Pharmaceuticals Inc
28/10/202421:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CNSPCNS Pharmaceuticals Inc
24/10/202417:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CNSPCNS Pharmaceuticals Inc
15/10/202423:24Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CNSPCNS Pharmaceuticals Inc
03/09/202414:00GlobeNewswire Inc.IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc.NASDAQ:CNSPCNS Pharmaceuticals Inc
06/08/202423:11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNSPCNS Pharmaceuticals Inc
06/08/202422:53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CNSPCNS Pharmaceuticals Inc
05/08/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CNSPCNS Pharmaceuticals Inc
02/08/202422:11Edgar (US Regulatory)Form SC 13D - General Statement of Acquisition of Beneficial OwnershipNASDAQ:CNSPCNS Pharmaceuticals Inc
31/07/202418:32Edgar (US Regulatory)Form RW - Registration Withdrawal RequestNASDAQ:CNSPCNS Pharmaceuticals Inc
30/07/202423:15Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CNSPCNS Pharmaceuticals Inc
19/07/202423:12Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:CNSPCNS Pharmaceuticals Inc
12/07/202422:30Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CNSPCNS Pharmaceuticals Inc
09/05/202423:28Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CNSPCNS Pharmaceuticals Inc
31/01/202422:27Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CNSPCNS Pharmaceuticals Inc
13/10/202300:01Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:CNSPCNS Pharmaceuticals Inc
15/05/202314:40Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CNSPCNS Pharmaceuticals Inc
15/05/202314:39Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CNSPCNS Pharmaceuticals Inc
09/05/202323:11Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CNSPCNS Pharmaceuticals Inc
02/05/202301:00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CNSPCNS Pharmaceuticals Inc
31/03/202323:05Edgar (US Regulatory)Annual Report (10-k)NASDAQ:CNSPCNS Pharmaceuticals Inc
29/03/202315:05PR Newswire (US)CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight EventNASDAQ:CNSPCNS Pharmaceuticals Inc
13/03/202312:05PR Newswire (US)CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank IssuesNASDAQ:CNSPCNS Pharmaceuticals Inc
09/03/202315:05PR Newswire (US)CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in SwitzerlandNASDAQ:CNSPCNS Pharmaceuticals Inc
14/02/202318:24Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CNSPCNS Pharmaceuticals Inc
07/02/202314:45PR Newswire (US)CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBMNASDAQ:CNSPCNS Pharmaceuticals Inc
12/01/202314:45PR Newswire (US)CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in PolandNASDAQ:CNSPCNS Pharmaceuticals Inc
05/01/202315:05PR Newswire (US)CNS Pharmaceuticals to Present at the Virtual Investor 2023 Companies to Watch EventNASDAQ:CNSPCNS Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CNSP

La tua Cronologia

EU
XS1796079488
ING Groep Fixed to Float...
TSXV
AGH.H
Canadian Silver Hunter
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network